		ICMJE DISCL	OSURE FORM	
Dat	te: Sep 14, 2021			
Υοι	ur Name:Zan Zhang			
			lated IncRNAs in the tumor microenvironment of stage	II - III
	- -			
Ma				
rela par to t	ated to the content of your ties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensionships. the manuscript.	
	tem #1 below, report all su time frame for disclosure i		d in this manuscript without time limit. For all other ite	∍ms,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)	planning of the work	
1	All support for the present	Time frame: Since the initial This study was funded by	planning of the work	
1	All support for the present	i inis study was tunded by		

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138 This study was funded by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138, and the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep 14, 2021	
	f immune related IncRNAs in the tumor microenvironment of stage II $ extstyle -$ II
related to the content of your manuscript. "R parties whose interests may be affected by th	o disclose all relationships/activities/interests listed below that are Related" means any relation with for-profit or not-for-profit third he content of the manuscript. Disclosure represents a commitment icate a bias. If you are in doubt about whether to list a that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138 This study was funded by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138, and the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep 14	, 2021
	Changyuan Yu
•	e:_ Comprehensive analysis of immune related IncRNAs in the tumor microenvironment of stage II \neg III representations.
	ber (if known):
related to the co	f transparency, we ask you to disclose all relationships/activities/interests listed below that are ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third sterests may be affected by the content of the manuscript. Disclosure represents a commitment
to transparency	and does not necessarily indicate a bias. If you are in doubt about whether to list a ivity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138 This study was funded by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138, and the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an "X" next to the following statement to indicate your agreement:

Date: Sen 1/1.	2021
	Zhengtai Li
Manuscript Title:	Comprehensive analysis of immune related IncRNAs in the tumor microenvironment of stage II – III
	per (if known):
related to the co	transparency, we ask you to disclose all relationships/activities/interests listed below that are attent of your manuscript. "Related" means any relation with for-profit or not-for-profit third
to transparency a	erests may be affected by the content of the manuscript. Disclosure represents a commitment nd does not necessarily indicate a bias. If you are in doubt about whether to list a rity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138 This study was funded by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138, and the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an "X" next to the following statement to indicate your agreement:

	, 2021					
Your Name: Lida Xu						
Manuscript number (if known):						
related to the coparties whose into transparency	f transparency, we ask you to disclose all relationships/activities/interests listed below that are ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third neests may be affected by the content of the manuscript. Disclosure represents a commitment and does not necessarily indicate a bias. If you are in doubt about whether to list a civity/interest, it is preferable that you do so.					
The following q	uestions apply to the author's relationships/activities/interests as they relate to the <u>current</u>					

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138 This study was funded by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)					
	Time frame: past 36 months						
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None					
4	Consulting fees	None					

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was funded by the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science) SKLPBS2138, and the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an "X" next to the following statement to indicate your agreement: